Federica Zotta
Overview
Explore the profile of Federica Zotta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
53
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferri M, Zotta F, Donadelli R, Dossier C, Duneton C, El-Sissy C, et al.
Pediatr Nephrol
. 2024 Apr;
39(11):3263-3269.
PMID: 38632123
Background: Between 5 and 50% of atypical hemolytic uremic syndrome (aHUS) cases in children are caused by autoantibodies against complement factor H (CFH). Given the acquired autoimmune nature of the...
2.
Riganati M, Zotta F, Candino A, Conversano E, Gargiulo A, Scarsella M, et al.
Front Immunol
. 2024 Apr;
15:1379924.
PMID: 38629076
Introduction: The clinical evolution of steroid-sensitive forms of pediatric idiopathic nephrotic syndrome (INS) is highly heterogeneous following the standard treatment with prednisone. To date, no prognostic marker has been identified...
3.
Vivarelli M, Colucci M, Algeri M, Zotta F, Emma F, LErario I, et al.
JCI Insight
. 2023 Aug;
8(18).
PMID: 37561590
BACKGROUNDSevere forms of idiopathic nephrotic syndrome (INS) require prolonged immunosuppressive therapies and repeated courses of high-dose glucocorticoids. Mesenchymal stromal cells (MSCs) have promising immunomodulatory properties that may be employed therapeutically...
4.
Colucci M, Angeletti A, Zotta F, Carsetti R, Lugani F, Rava L, et al.
Kidney Int
. 2023 Jun;
104(3):577-586.
PMID: 37385541
B-cell depleting anti-CD20 monoclonal antibodies, such as rituximab, have proven efficacy in children with frequently-relapsing/steroid-dependent nephrotic syndrome (FR/SDNS). However, drug-free remission is variable and specific baseline markers predictive of relapse...
5.
Zotta F, Diomedi-Camassei F, Gargiulo A, Cappoli A, Emma F, Vivarelli M
Pediatr Nephrol
. 2023 Jun;
38(12):4197-4201.
PMID: 37306717
Background: C3 glomerulonephritis (C3GN) is a subtype of C3 glomerulopathy (C3G), characterized by dysregulation of the alternative pathway of complement and by dominant C3 by immunofluorescence on the kidney biopsy....
6.
Zotta F, Vivarelli M, Carsetti R, Cascioli S, Emma F, Colucci M
Pediatr Nephrol
. 2021 Oct;
37(2):455-459.
PMID: 34661744
Background: The therapeutic efficacy of B cell-depleting anti-CD20 treatment in both pediatric and adult steroid-sensitive nephrotic syndromes (SSNS) suggests that B cells play a pathogenic role in the disease. In...
7.
Colucci M, Piano Mortari E, Zotta F, Corrente F, Concato C, Carsetti R, et al.
Front Immunol
. 2021 Mar;
12:602826.
PMID: 33776994
Idiopathic nephrotic syndrome is a childhood renal disease characterized by a damage of the glomerular filtration barrier leading to an intense leakage of proteins into the urine. This severe proteinuria...
8.
Zotta F, Vivarelli M, Emma F
Pediatr Nephrol
. 2021 Mar;
37(2):303-314.
PMID: 33665752
Steroid-sensitive nephrotic syndrome (SSNS) is a rare condition that develops primarily in preadolescent children after the age of 1 year. Since the 1950s, oral corticosteroids have been the mainstay of...
9.
Zotta F, Di Stasio E, Manzione A, Pirozzi N, Stoppacciaro A, Mene P
G Ital Nefrol
. 2019 Jun;
36(3).
PMID: 31251003
Introduction: Immunosuppressive treatment of patients with idiopathic membranous nephropathy (IMN) is debated due to its possible side effects. The 2012 KDIGO guidelines suggest alkylating agents as first choice therapy. The...
10.
Zotta F, Guzzo I, Morolli F, Diomedi-Camassei F, Dello Strologo L
Pediatr Nephrol
. 2018 Jul;
33(11):2167-2175.
PMID: 29980849
Background: Kidney transplantation is the best treatment for children with end-stage kidney disease. Early results have improved, but late graft loss is still a major problem. Non-invasive, fully reliable early...